The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Urotensin II (UII) is a potent vasoactive peptide that binds to the urotensin receptor-coupled receptor-14 (known as UT) and exerts a wide range of actions in humans and experimental animals. We tested the hypothesis that UII gene deletion or UT blockade ameliorate experimental atherosclerosis. Methods and Results-We observed a significant reduction in weight gain, visceral fat, blood pressure, circulating plasma lipids, and proatherogenic cytokines and improvement of glucose tolerance in UII knockout mice compared with wild type (P<0.05). Deletion of UII after an apolipoprotein E knockout resulted in a significant reduction in serum cytokines, adipokines, and aortic atherosclerosis compared with apolipoprotein E knockout mice. Similarly, treatment of apolipoprotein E knockout mice fed on high-fat diet with the UT antagonist SB657510A reduced weight gain, visceral fat, and hyperlipidemia and improved glucose tolerance (P<0.05) and attenuated the initiation and progression of atherosclerosis. The UT antagonist also decreased aortic extracellular signal-regulated kinase 1/2 phosphorylation and oxidant formation and serum level of cytokines (P<0.05). Conclusion-These findings demonstrate for the first time the role of UII gene deletion in atherosclerosis and suggest that the use of pharmaceutical agents aimed at blocking the UII pathway may provide a novel approach in the treatment of atherosclerosis and its associated precursors such as obesity, hyperlipidemia, diabetes mellitus, and hypertension. (Arterioscler Thromb Vasc Biol. 2012;32:1809-1816.) 
U rotensin II (UII) is a vasoactive peptide originally found in teleost fish with homologs later discovered in several other species including mice, rats, frogs, and humans. [1] [2] [3] [4] In the latter, UII is an 11 amino acid peptide with highly conserved C-terminal hexapeptide and disulfide bridge between 2 cysteine residues. Subsequent studies revealed that UII was the ligand for its own receptor, the rat orphan G-proteincoupled receptor-14/sensory epithelial neuropeptide-like receptor, which in humans is now known as the urotensin receptor (UT). 5, 6 Although it is considered the most potent vasoconstrictor peptide, studies of UII in various species have shown varied actions depending on the type of vessel, source of UII and the integrity of the endothelium, and the presence or absence of a disease state. [5] [6] [7] [8] [9] [10] [11] In a study of 2 treatment groups, physiologically healthy individuals and patients with chronic heart failure, UII had vasodilator effects in healthy individuals, whereas patients with chronic heart failure showed vessel constriction. 9 Plasma UII levels are elevated in patients with confirmed atherosclerosis. 12, 13 UII plasma levels predicted a 1.6-fold higher risk of carotid plaque formation when compared with currently recognized risk factors. 13 UII and the UT are both upregulated in atherosclerotic lesions. [14] [15] [16] [17] We had demonstrated increased UII expression in areas of atherosclerotic plaques by immunocytochemistry and real-time polymerase chain reaction. 14, 16 UII is upregulated throughout the vessel wall (in endothelial, myointimal, and medial smooth muscle cell [SMC] layers) in human coronary atherosclerosis. 16 In human abdominal aortic aneurysm and carotid atherosclerotic extracts, UT mRNA expression is increased. 14 Among the inflammatory cell population, lymphocytes appear to be the largest producers of UII, whereas monocytes and macrophages appear to express the highest levels of UT. 14 Inflammatory mediators such as lipopolysaccharide, tumor necrosis factor-α, and interferon-γ are known to upregulate UT mRNA expression. 18 Indeed, UIImediated chemotaxis has been demonstrated in monocytes to be ras homolog gene family, member A/rho-associated, coiled-coil containing protein kinase dependent. 18 UII also upregulated acetyl-Coenzyme A acetyltransferase 1 activity resulting in increased production of foam cells in lesions. 19 We have recently demonstrated that selective UT blockade significantly reduced the number of acetyl-Coenzyme A acetyltransferase 1 producing cells in the atherosclerotic plaque of apolipoprotein E (apoE) knockout (KO) mice fed a high-fat diet (HFD). 20 In addition, UII has direct effects on reactive oxygen species (ROS) levels by activating nicotinamide adenine dinucleotide phosphate oxidase subunits p22phox and nicotinamide adenine dinucleotide phosphate oxidase 4. 19, 21, 22 ROS has also been shown to play a critical role in UII signal transduction. 23 Thus, the effects of UII and ROS are intimately related along the progression of atherosclerosis.
Although a recent study has shown that chronic infusion of UII increases atherosclerosis in apoE KO mice, 24 the exact role of UII in this disease process remains to be elucidated. Here, we used molecular and pharmacological approaches to determine the role UII plays in atherosclerosis. First, we generated UII KO mice and cross bred them with apoE KO mice. Second, we used a selective UT antagonist to determine the role of UII in the initiation and progression of atherosclerosis in apoE KO mice fed a HFD.
Materials and Methods

Targeting the PreproUII Gene
Gene targeting was performed in E14 embryonic stem cells using standard homologous recombination ( Figure 1A ). Generation of UII mutant mice is described in the online-only Data Supplement.
Pharmacological Study
ApoE KO mice (C57Bl6/J) were purchased from Jackson Laboratories (Bar Harbor, ME). Male and female mice were divided into 3 groups as follows.
Prevention Groups
apoE KO mice (6-week-old) were placed on the same HFD mentioned earlier containing either 50 mg/kg per day SB657510A (SB) or 1% methyl cellulose (V) for 10 weeks.
Regression Group (I)
apoE KO mice (6-week-old) were placed on the same HFD described above for 10 weeks, after which they were continued on a HFD containing either 50 mg/kg per day SB657510A (SB) or 1% methyl cellulose (V) for the ensuing 10 weeks.
Regression Group (II)
apoE KO mice (6-week-old) were placed on HFD for 10 weeks, after which they were placed on normal diet containing either 50 mg/kg per day SB657510A (SB) or 1% methyl cellulose (V) for the ensuing 10 weeks.
Food intake was monitored daily and did not significantly differ among all experimental groups. Body weight was measured at the beginning of the study and thereafter once weekly until the end of the study. Unless indicated, data shown here represent that of male mice.
Blood Pressure Analysis
First, blood pressure was monitored using the tail cuff technique. Second, before euthanizing, adult male mice were anesthetized with ketamine-xylazine (IM, 87 mg/kg:13 mg/kg), and a fluid-filled catheter was then inserted into the carotid artery for blood pressure monitoring.
Statistical Analyses
All values are presented as mean±SE. Multigroup comparisons were analyzed using ANOVA with the Tukey post hoc test. The 2 groups were compared using the Student t test. P<0.05 was considered statistically significant. All statistical analyses were carried out using SPSS version 11.5 (SPSS Inc, Chicago, IL).
Results
UII KO Study
Deletion of the UII gene was confirmed by reverse transcription polymerase chain reaction ( Figure 1A ) and radioimmunoassay ( Figure 1B) . The latter showed a significant reduction of UII immunoreactivity in the aorta. The remaining immunoreactivity is likely to represent urotensin-related peptide because the assay does not distinguish between the 2 molecules. UII KO mice were all born alive and healthy. Their growth curve revealed that male UII KO mice exhibit a lean profile compared with their wild type when fed normal diet. This phenotype was more apparent and reached statistical significance . Levels of UII-like immunoreactivity were determined by radioimmunoassay (RIA). Proteins were extracted in acid-acetone followed by centrifugation. The RIA incubation mixture consisted of hUII or tissue extract, monoclonal antibody (mAb)UII-17, [ 125 I]hUII, and standard buffer (50 mmol/L phosphate buffer [pH7.4] containing 10 μmol/L Na-EDTA and 0.1% BSA). After a 16-hour incubation at 4°C, bound and free ligands were separated using a secondary goat antimouse antibody (BioMagnectic Goat Antimouse IgG; Qiagen, Hilden, Germany). *P<0.001.
when the animals were placed on the HFD (Figure 2A ; Table  I in the online-only Data Supplement). Female mice on either diet did not exhibit a significant difference in weight gain. Food intake did not differ between UII KO (2.83±0.08 g/day) and wild-type (2.97±0.10 g/day) mice. UII KO mice also appeared more active and alert than their wild-type counterparts, and they exhibited significantly lower mean and systolic arterial blood pressure compared with wild-type mice ( Table  II in the online-only Data Supplement). There was no significant difference between wild-type and UII KO mice in terms of glucose or insulin tolerance when mice were fed normal diet. In contrast, when fed the HFD, the UII KO mice showed a significant improvement in glucose tolerance compared with wild type ( Figure 2B ). HFD-fed UII KO mice had <80% low-density lipoprotein (LDL)-cholesterol compared with wild type, and they both did not exhibit aortic atherosclerosis. Serum levels of free fatty acid were significantly lower in HFD-fed UII KO (0.63±0.06 mmol/L) compared with wildtype (1.00±0.059 mmol/L; P<0.05) mice. UII KO mice had greater serum lipoprotein particles containing apoA-I than wild type ( Figure 3A) . Similarly, the media of hepG2 cell culture incubated with serum from UII KO mice contained more lipoprotein particles containing apoA-I particles than those incubated with serum of wild-type mice ( Figure 3B ). Visceral adipocyte diameter of UII KO mice was significantly smaller than that of wild-type mice ( Figure 4A and 4B; 696±31 versus 2019±54 pixes; P<0.01).
When UII KO mice were cross bred with apoE KO mice, the resulting apoE KO/UII KO (DKO) mice exhibited reduced mean arterial blood pressure (100.63±3.61 versus 121.31±5.71; P<0.05), serum very-low-density lipoproteincholesterol (23±2%), triglycerides (50±3%), and aortic atherosclerosis compared with apoE KO mice ( Figure 4C and 4D), and increased cholesterol efflux of peritoneal macrophages. Serum levels of inflammatory cytokines, such as monocyte chemoattractant protein-1, monokine induced by γ-interferon (MIG), and keratinocyte chemoattractant, were reduced in UII KO compared with wild-type mice ( Figure 5A ). Similarly, DKO mice exhibited either a reduction or complete elimination of soluble intercellular adhesion molecule-1, monocyte chemoattractant protein-1 (Japanese encephalitis) MIG, and tissue inhibitor of metalloproteinase-1 compared with apoE KO mice ( Figure 5B ). Adipokines, such as dipeptidyl peptidase-4, endocan (endothelial cell-specific molecule-1), and insulin-like growth factor-binding protein-2, -3, -5, and -6 were reduced in the serum of DKO mice compared with apoE KO mice ( Figure 5C ). Analysis of the histological and immunohistochemical staining of aortic root of DKO mice revealed the presence of less atherosclerotic lesion in the aortic root of DKO mice compared with apoE KO mice ( Figure 6 ). The latter showed more cholesterol clefts, with less α-SMC staining in the atherosclerotic cap (3.73% of lesion), whereas the DKO mice exhibited mainly atheroma with foam cells and abundant presence of α-SMC staining of the surface of the atherosclerotic cap (5.85% of lesion; P<0.02; Figure 6 ). Western blotting and immunohistochemistry revealed a significant reduction in nitrotyrosine, 
Discussion
Atherosclerosis is the main cause of morbidity and mortality of cardiovascular diseases. 25 Epidemiological studies have shown that atherosclerosis is associated, among other things, with the presence of serum hyperlipidemia and hyperglycemia, obesity, and hypertension. 25 The vasoactive peptide UII modulates vascular tone, blood pressure, and insulin release. 12 In the present study, we demonstrate that deletion of the UII gene in mice results in decreased body mass, visceral fat and blood pressure, and improved insulin and glucose tolerance. Furthermore, in the pathological setting of experimental atherosclerosis, UII deletion in apoE KO mice fed a HFD led to reduced aortic atherosclerosis and proatherogenic inflammatory cytokines and adipokines. Similarly, the use of the selective UT blocker SB657510A in apoE KO mice fed a HFD significantly reduced body weight gain, blood pressure, serum hyperlipidemia and hyperglycemia, circulating cytokines and aortic atherosclerosis, ERK1/2 and P44/42 mitogen-activated protein kinase phosphorylation and oxidant formation, and stabilized the lesion. Finally, patients with all parameters of the metabolic syndrome exhibited elevated levels of plasma UII. These findings demonstrate that UII is an important mediator of atherosclerosis and its associated sequels. A previous pharmacological study had shown that intracerebroventricular injection of UII produces anxiogenic effects and increases water and food intake in the mouse. 26 Plasma UII level also correlates positively with body weight in the Hong Kong Chinese population. 27 On the other hand, we have recently reported that UT KO mice exhibited a lean profile. 28 In the present study, we monitored food intake and observed no significant difference between UII KO and wild-type mice. However, UII KO mice exhibited a significant reduction in body weight gain and visceral fat content compared with wildtype mice. In addition, apoE KO mice fed a HFD and treated with SB657510A exhibited similar reduction in weight gain to that of UII KO mice suggesting that UII plays an important role in the control of body mass and fat content in a manner independent of appetite suppression. Furthermore, the reduction in body weight gain appears to be related to gender and warrants further investigation.
Intravenous administration of UII led to increase in mean arterial blood pressure in cats, 29 rats, 30 and sheep. 31 UII plasma levels and systolic blood pressure mirror one another. 27 UIIlike immunoreactivity was found in high concentrations in patients with essential hypertension or with hypertensive renal disease. 32 The genetic variant, 3836C>T (S89N) in the UII gene is associated with essential hypertension in a Northwestern Chinese population. 33 Moreover, elevated plasma level of UII and expression of UII and the UT have been reported in experimental animals of hypertension, 34, 35 and a recent study has shown significant correlation between blood pressure and UII levels in patients with carotid atherosclerosis and vascular dementia. 36 Here we demonstrated that UII KO mice tend to exhibit decreased mean arterial and, particularly, systolic blood pressure than wild type. Similarly, the use of UT antagonist SB657510A significantly reduced mean blood pressure and systolic pressure in apoE KO mice fed a HFD. A recent study has suggested that soluble epoxide hydrolase might play an important role in mediating UII vascular effects. 37 Our data have shown that UII deletion is associated with a reduction in aortic soluble epoxide hydrolase protein expression. These findings point to an important role for UII in modulating blood pressure. Both patients with atherosclerosis and apoE KO mice are known to exhibit elevated serum levels of LDL and triglycerides. 25 The extent of fat in the diet will influence the serum level of lipids, as well as the extent of atherosclerotic lesions. UII has been shown to influence lipase activity in the cohoe salmon, 38, 39 and UII plasma level is associated with LDL in atherosclerosis. 36 However, since those initial studies, little has been done to assess the effects of UII on serum lipids. Here, we demonstrated for the first time that deletion of the UII gene alone or in the pathological setting of apoE KO in mice fed a HFD resulted in a decrease in serum LDL and triglycerides and an increase in serum pre-β highdensity lipoprotein as evident in the increase of lipoprotein particles containing apoA-I. Furthermore, UT blockade with SB657510A again reduced serum lipid in apoE KO mice fed a HFD. The mechanism by which UII modulates serum lipid is under investigation in our laboratory. Indeed, microarray analysis of samples from SB657510A-treated mice have shown a downregulation of a number of adipokines known to play an important role in lipid metabolism (data not shown). These findings demonstrate an important role for UII in modulating serum lipid and open the possibility for the use of UT antagonists as therapeutic modality in reducing circulating LDL and trigylecrides.
Atherosclerosis is associated with a buildup of cholesterol increasing vessel wall thickness and the induction of a chronic inflammatory response that includes the infiltration of monocytes and macrophages. 25 We had previously shown that inflammatory cells express both UII and UT. 14 Furthermore, inflammatory mediators, such as lipopolysaccharide, tumor necrosis factor-α, and interferon-γ have been shown to induce UT mRNA expression 18 alluding to the chemotaxis and signaling roles that UII may play in the progression of atherosclerosis. Furthermore, chemotaxis effects of UII have been demonstrated in monocytes. 18 UII is also known to induce expression of cellular adhesion molecules in coronary endothelial cells. 12 Here, we demonstrated for the first time that UII deletion in combination with ApoE KO reduces protein expression of inflammatory cytokines, such as soluble intercellular adhesion molecule-1, monocyte chemoattractant protein-1, MIG, and tissue inhibitor of metalloproteinase-1, known to play an important role in the pathogenesis of atherosclerosis. 25 These data were further supported by the findings that the UT blocker SB657510A also reduced the serum protein level of C5a, tissue inhibitor of metalloproteinase-1, M-CSF, soluble intercellular adhesion molecule-1, and MIG in apoE KO mice fed on HFD.
Dyslipidemia associated with atherosclerosis leads to increases in LDL-cholesterol and mildly oxidized LDL, which subsequently cause development of atherosclerotic plaques through stimulation of ROS formation and vascular SMCs differentiation and proliferation. 25 Indeed, studies have shown that UII increases the mitogenic effects of mildly oxidized LDL on vascular SMCs in a synergistic manner via both G-proteindependent effects on protein kinase C and ERK. 21, [40] [41] [42] UII has also direct effects on ROS levels by activating nicotinamide adenine dinucleotide phosphate oxidase subunits p22phox and nicotinamide adenine dinucleotide phosphate oxidase 4. 19, 21, 22 ROS has also been shown to play a critical role in UII signal transduction. 23 Here, we demonstrated that deletion of the UII gene and the use of SB657510A significantly reduced the aortic expression of nitrotyrosine, a marker of protein oxidation by peroxynitrite, and 4-hydroxy 2-nonenal, a sensitive marker of lipid peroxidation and oxidative stress, both known to play an important role in the pathogenesis of atherosclerosis. 43, 44 These findings were also associated with a significant reduction in aortic ERK1/2 and P44/42 mitogen-activated protein kinase phosphorylation. Thus, the effects of UII and ROS appear intimately related along the progression of atherosclerosis, and the use of UT blocker significantly reduces aortic oxidative stress.
Hyperglycemia and insulin resistance are interrelated components of atherosclerosis, and both are related to UII. 5 Both UII and the UT are expressed in the pancreatic islets. 45, 46 In salmon, UII increases glucose-6-phosphatase activity and reduces liver glycogen content. 39 UII inhibited glucose-and arginine-induced insulin responses in the rat pancreas. 45, 46 In humans, single nucleotide polymorphism analysis of the Hong Kong and Han Chinese and Japanese populations confirmed that certain UT gene haplotypes are associated with insulin resistance and pancreatic β-cell function. [47] [48] [49] [50] A recent study has also demonstrated an association between UT gene and type II diabetes mellitus. 51 Plasma UII levels were ≈2× as high in patients with type II diabetes mellitus without proteinuria when compared with healthy subjects (7.8 fmol/mL versus 4.4 fmol/mL). 52 UII serum level and UII binding, as well as UT protein and mRNA expression, are all significantly enhanced in the skeletal muscle of 2DM mice. 53 Here, we demonstrated that UII deletion significantly reduced serum insulin and glucose, and improved glucose and insulin tolerance. Furthermore, the use of SB657510A significantly improved glucose tolerance in apoE KO mice. More importantly, adipokines, such as dipeptidyl peptidase-4, endocan, and insulin-like growth factor-binding proteins known to play an important role in obesity and diabetes mellitus [54] [55] [56] were all reduced in DKO mice compared with apoE KO mice. These findings again reinforce the role UII plays in insulin release and suggest a role for UT antagonists in the management of the metabolic syndrome.
Although we and others have previously examined the role of UII in atherosclerosis, the effects of UII deletion on the extent and type of atherosclerotic plaque and the mechanism involved had not been investigated. Here, we demonstrated that UII deletion and chronic receptor blockade did not only reduce the lesion but resulted in a more stable lesion by increasing the percentage of α-SMC and decreasing the percentage of carbohydrate-binding protein 35-producing cells in the atherosclerotic plaque. Furthermore, we show for the first time that SB657510A significantly reduced the extent of established atherosclerotic plaque in male apoE KO mice fed a HFD. We had previously shown that although UT deletion resulted in a lean profile, there was an increase in serum lipid and atherosclerosis. 29 The discrepancy between UT and UII deletion could be attributed to the possibility of UT subtypes as evident from previous studies. For example, Coy et al 57 demonstrated that although the somatostatin analog (Cpa-c[d-Cys-Pal-d-Trp-Lys-Val-Cys]-Cpa-amide) was able to inhibit UII-induced phasic contraction in the rat isolated aorta, the peptidic moiety was unable to block tonic contraction. In addition, Camarda et al 58 demonstrated that [Orn 8 ]UII acts as a full agonist at human embryonic kidney 293 cells expressing recombinant rat UT but is a competitive antagonist in rat isolated aorta. Furthermore and before these observations, Northern blotting analysis of multiple human tissues showed different UT transcript sizes. 59 The other possible explanation to the opposing effect may stem from the effect of UT gene deletion on hepatocytes function. 60 This is further supported by the fact that the receptor antagonist used in the present study had no effect on cholesterol metabolism or hepatic steatosis (data not shown).
In summary, we used molecular and pharmacological approaches to determine the role of UII in the pathogenesis of atherosclerosis and successfully demonstrated that UII plays an important role in atherosclerosis through modulating body weight mass, blood pressure, and serum lipid, sugar, cytokines, adipokines, and oxidant formation. Furthermore, UII contributed to plaque remodeling and stability. These findings point to a potentially important role for future therapeutic approaches aimed at blocking the UT in the management of atherosclerosis and its associated sequels.
